throbber
Inter Partes Review of US 8,278,351
`Ex. 1042, Brenna Declaration
`
`(Ex. 1054; March 16, 2012 Declaration of Faustinus Yeboah, ’348
`
`
`
`Reexamination at ¶ 36.)
`
` Another Neptune declarant, Dr. Shahidi, also
`
`acknowledged that extractions resulting from the Beaudoin process contain the
`
`claimed phospholipids:
`
`As Beaudoin reports an oil potentially with a small amount of the
`
`phospholipid containing two of EPA and DHA (i.e. about 0.1 to 1% ), it is my
`
`opinion that this is not a biologically effective amount. As the claims of the ’348
`
`patent are directed to biologically effective amounts of this composition, they are
`
`distinct from Beaudoin.
`
`(Ex. 1056; March 16, 2012 Declaration of Fereidoon Shahidi, ’348
`
`Reexamination, at ¶ 22.)
`
`4.1.2.4.
`
`Conclusion on Obviousness
`
`(i) Claims 1-94 of the ’351 patent are obvious over Beaudoin I (Ex.
`
`1002) in view of Bergelson (Ex. 1017)
`
`384. Claims 1-94 are obvious over Beaudoin I in view of Bergelson.
`
`385. As established above, Beaudoin I provides each element of claims 1-
`
`94 either expressly or
`
`inherently. The declaratory evidence conclusively
`
`
`
`201
`
`00000201
`
`

`
`Inter Partes Review of US 8,278,351
`Ex. 1042, Brenna Declaration
`
`
`
`establishes the inherent presence of the claimed phospholipids in Beaudoin I
`
`extracts from both E. pacifica and E. superba.
`
`386. There are no data in the ‘351 patent that compares the biological
`
`effectiveness of the claimed phospholipids to phospholipids with only one EPA or
`
`DHA attached. Likewise, there are no data that establishes the criticality of any of
`
`the other components listed in the independent and dependent claims. The
`
`extraction methods described in ‘351 patent are essentially the same as described
`
`in Table 19 of Beaudoin I. Thus, the extracts disclosed in Beaudoin I would be
`
`very similar in composition to the ‘351 extracts and necessarily include the
`
`components listed in the independent and dependent claims. To the extent there
`
`are any differences, it would have been routine optimization to provide the claimed
`
`amounts of extract components absent a showing of criticality.
`
`387. Patentee has also argued that the Beaudoin I extracts are not suitable
`
`for human consumption because of the solvent content in the extracts. Bergelson
`
`discloses that is well known to remove solvent from lipid extracts under gentle
`
`conditions by rotary evaporation.
`
`388. Beaudoin I is directed to the production of phospholipid extracts from
`
`marine sources, including krill, for human consumption. Beaudoin I contains a
`
`detailed protocol for extraction in Table 19, specifying that solvent may be
`
`removed under reduced pressure. Bergelson teaches that solvent can be removed
`202
`
`
`
`00000202
`
`

`
`Inter Partes Review of US 8,278,351
`Ex. 1042, Brenna Declaration
`
`
`
`by rotary evaporation (i.e., under reduced pressure) under mild temperature
`
`conditions. Ex. 1002, p. 10-11. Thus, there is a motivation to combine the
`
`references. A person of ordinary skill in the art would be motivated to remove
`
`solvent from the krill extracts of Beaudoin I by rotary evaporation as described in
`
`Bergelson to provide a krill extract with a desired content of phospholipids, EPA
`
`and DHA as well as other components naturally present in krill and presented in
`
`the claims. The person of skill in the art would be motivated to remove solvent to
`
`levels suitable for human consumption as Beaudoin clearly teaches the desirability
`
`of krill oil for both oral administration and topical administration as a cosmetic.
`
`The person of skill in the art would likewise be motivated to process the extracts so
`
`as to maintain the phospholipid content (i.e., avoid phospholipid degradation)
`
`because Beaudoin I teaches the desirability of the recovery of total lipids.
`
`389. A person of skill in the art would have a reasonable expectation of
`
`success in arriving at the claimed invention because the methods of Beaudoin I are
`
`essentially the same as those described in the ‘351 patent. Thus, the concentration
`
`of lipids in the extracts resulting from the Beaudoin I extraction process would be
`
`essentially the same as the concentrations specified in the claims. The extracts
`
`could easily be made suitable for human consumption by rotary evaporation as
`
`described in Bergelson.
`
`
`
`203
`
`00000203
`
`

`
`Inter Partes Review of US 8,278,351
`Ex. 1042, Brenna Declaration
`
`
`
`(ii) Claims 1-94 are unpatentable under 35 USC 103(a) over Beaudoin I
`
`(Ex. 1002) in view of the 2001 Prospectus (Ex. 1011), 2001 Press Release (Ex.
`
`1012) and Bergelson (Ex. 1017)
`
`390. Claims 1- 94 are obvious over Beaudoin I in view of the 2001
`
`Prospectus, 2001 Press Release and Bergelson. As discussed above, Beaudoin I
`
`provides each element of claims 1-94 either expressly or inherently. The
`
`declaratory evidence conclusively establishes the inherent presence of the claimed
`
`phospholipids in Beaudoin I extracts from both E. pacifica and E. superba.
`
`391. In addition to its arguments that the Beaudoin I extracts do contain
`
`meaningful amounts the claimed phospholipids, Patentee has argued that the
`
`claimed phospholipids are absent in the Beaudoin I extracts because they were
`
`degraded by heating. The citation of the 2001 Prospectus and 2001 Press release
`
`address this alleged deficiency as they describe the Beaudoin I process is a “cold
`
`extraction” process. Following the Beaudoin I protocol and using solvent
`
`evaporation techniques known in the art (e.g., as described in Bergelson) would
`
`produce an undegraded krill oil. The 2001 Prospectus states that the Beaudoin
`
`I/OceanExtractTM process is a cold extraction process that preserves the
`
`biological activity of the lipid substances, results in minimal alterations to the
`
`lipids, and is suitable for human consumption. Ex. 1011 at 13. The 2001 Press
`
`Release states that the Beaudoin I/OceanExtractTM process is a “cold process that
`204
`
`
`
`00000204
`
`

`
`Inter Partes Review of US 8,278,351
`Ex. 1042, Brenna Declaration
`
`
`
`preserves the biological activity and stability of the nutritional qualities intrinsic to
`
`the most highly sought substances of Krill, such as its powerful antioxidants,
`
`phospholipids and Omega-3-6-9 fatty acids” and produces a krill extract suitable
`
`for human consumption. Ex. 1012 at 1. Thus, krill phospholipid extracts produced
`
`according to the Beaudoin I/OceanExtractTM process would be in all aspects
`
`identical to those claimed in the ‘351 patent. The disclosure of the 2001
`
`Prospectus and Press Release is entirely consistent with the protocols in Beaudoin I
`
`which describe the preferred extraction process which a) does not include a heating
`
`step and b) specifies cold conditions for extraction (i.e., 4oC).
`
`392. Beaudoin I is directed to the production of phospholipid extracts from
`
`marine sources, including krill, for human consumption. Beaudoin I contains a
`
`detailed protocol for extraction in Table 19, specifying that solvent may be
`
`removed under reduced pressure. The 2001 Prospectus and 2001 Press release
`
`state that the process disclosed in Beaudoin I and licensed from the University of
`
`Sherbrooke by Patentee is a cold extraction process. Bergelson teaches that
`
`solvent can be removed by rotary evaporation (i.e., under reduced pressure) under
`
`mild temperature conditions. Ex. 1017, p. 10-11. A person of ordinary skill in the
`
`art would be motivated to conduct extraction from krill under cold conditions and
`
`to remove solvent from the krill extracts of Beaudoin I by rotary evaporation as
`
`described in Bergelson to provide a krill extract with a desired content of
`205
`
`
`
`00000205
`
`

`
`Inter Partes Review of US 8,278,351
`Ex. 1042, Brenna Declaration
`
`
`
`phospholipids, claimed phospholipids, EPA and DHA as well as other components
`
`naturally present in krill and presented in the claims. The person of skill in the art
`
`would be motivated to remove solvent to levels suitable for human consumption as
`
`Beaudoin clearly teaches the desirability of krill oil for both oral administration
`
`and topical administration as a cosmetic. The person of skill in the art would
`
`likewise be motivated to process the extracts so as to maintain the phospholipid
`
`content (i.e., avoid phospholipid degradation) because Beaudoin I teaches the
`
`desirability of the recovery of total lipids.
`
`393. A person of skill in the art would have a reasonable expectation of
`
`success in arriving at the claimed invention because the methods of Beaudoin II are
`
`essentially the same as those described in the ‘351 patent. Thus, the concentration
`
`of lipids in the extracts resulting from the Beaudoin I extraction process would be
`
`essentially the same as the concentrations specified in the claims. The extracts
`
`could easily be made suitable for human consumption by rotary evaporation as
`
`described in Bergelson.
`
`(iii) Claims 1-94 are unpatentable under 35 USC 103(a) over Fujita (Ex.
`
`1005) in view of Watanabe (Ex. 1039), and further in view of Itano (Ex. 1009)
`
`and Yasawa (Ex. 1015).
`
`394. As discussed above, the declaratory evidence conclusively establishes
`
`the inherent presence of the claimed phospholipids in Fujita extracts from E.
`206
`
`
`
`00000206
`
`

`
`Inter Partes Review of US 8,278,351
`Ex. 1042, Brenna Declaration
`
`
`
`superba meal (claims 1, 19, 20 and 21), a fatty acid content of about 5% (Claim 4),
`
`PUFA and omega-3 content (claims 6 and 9) and the presence of Zn and Se in the
`
`Fujita extracts in the claimed amounts (claims 12-14). See Ground 4 and Claim
`
`Chart, supra. The remaining elements of claims 1 and 94 and dependent claims 2,
`
`3, 4, 22 and 23 (i.e., phospholipid content, triglycerides and other components, and
`
`astaxanthin) are explicitly disclosed in Fujita. Watanabe further describes
`
`properties of krill oil and a polar krill oil obtained by hexane extraction of krill
`
`meal (E. superba, Antarctic krill). See p. 682, col. 2, p. 685, col., 1, and p. 683
`
`Tables 1 and 2. Watanabe specifically discloses discloses the fatty acid
`
`composition (i.e., saturated and unsaturated fatty acids), free sterol (i.e.,
`
`cholesterol),
`
`fatty acid,
`
`
`
`triglyceride, diglyceride, monoglyceride, and
`
`sphingomyelin content of krill oil and krill polar oil extracts. These values are
`
`similar to those disclosed in the tables in dependent claims 15-18. Based on the
`
`similarity of these values, any values that are missing in Watanabe would be
`
`inherent. Itano describes concentrated krill phospholipid compositions. Itano at p.
`
`15. These compositions contained greater than 50% EPA and DHA, thus meeting
`
`the limitations of dependent claims 7 and 8 (>40% and 45% w/w PUFAs) and 10
`
`and 11 (>32% and 35% w/w DHA/EPA). Thus, the combined references meet
`
`each element of the claims, especially when none of the claimed concentrations of
`
`are critical as discussed above.
`
`
`
`207
`
`00000207
`
`

`
`Inter Partes Review of US 8,278,351
`Ex. 1042, Brenna Declaration
`
`395. Watanabe uses a hexane extraction from krill meal and acetone
`
`
`
`fractionation of phospholipids as described in Fujita. Itano discloses the
`
`desirability of krill phospholipids for use in foods and as nutritional supplements as
`
`well as specific concentrated krill phospholipid compositions. Yasawa describes
`
`different methods of formulating krill oil. A person of skill in the art would have
`
`been motivated to combine these four references because they teach methods for
`
`extraction and concentration of krill phospholipids and their incorporation into oral
`
`and topical dosage forms as well as into functional foods. There is a reasonable
`
`expectation of success because specific krill phospholipid extracts are disclosed
`
`that closely approximate the claimed values of the ‘351 krill extracts. Formulating
`
`the krill extracts so that they are suitable for human consumption and incorporating
`
`the extracts into oral and topical delivery forms and foods is well within the skill in
`
`the art.
`
`(iv) Claims 1-2 94 are unpatentable under 35 USC 103(a) over Fricke (Ex.
`
`1006) in view of Bergelson (Ex. 1017), and further in view of Yasawa (Ex.
`
`1015), Itano (Ex. 1009) and the WHO Bulletin (Ex. 1018)
`
`396. Claims 1-23 and 94 are obvious under 35 USC 103(a) over Fricke in
`
`view of Bergelson and further in view of Yasawa, Itano and the WHO Bulletin.
`
`The claim elements taught by Fricke are addressed above.
`
`
`
`208
`
`00000208
`
`

`
`Inter Partes Review of US 8,278,351
`Ex. 1042, Brenna Declaration
`
`397. Fricke specifically teaches that krill phospholipids have EPA (20:5 n-
`
`
`
`3) and DHA (22:6 n-3) at both sn-1 and sn-2 positions of PC and PE (See p. 826,
`
`Table 6), greater than 40% phospholipids (p. 821, Table 1) and greater than 15%
`
`omega-3 w/w (p. 823, Table 1). Le Grandois (Ex. 1013) further establishes that
`
`the claimed phospholipids are present in Folch extracts from krill oil. Thus, the
`
`Folch extraction technique is suitable for preserving the claimed phospholipids.
`
`Bergelson teaches removal of chloroform/methanol solvents from lipids by rotary
`
`evaporation. Thus, it was well within the skill of those in the art to produce
`
`extracts suitable for human consumption by the Folch extraction technique taught
`
`in Fricke. Yasawa (¶¶0008-19) and Itano (p. 16) further teach krill extracts that are
`
`suitable for human consumption (all claims), as well as incorporation of krill oil
`
`into capsules and syrups (Yasawa ¶¶0012-13; claims 24-46) and topical creams (¶¶
`
`Yasawa 0016; claims 70-93) and functional foods (Itano, p. 15; claims 47-69).
`
`Thus, the combined references teach each element of the independent claims.
`
`398. The Fricke extracts contained the claimed levels of phospholipids
`
`(claims 2, 3, 25, 26, 48, 49, 72, and 73; p. 82, Table 1 (from 39.6% to 42.5% intact
`
`phospholipids)), triglycerides and monoglycerides (claims 4, 27, 50 and 74; p. 822,
`
`Table 1), about 5% w/w free fatty acids (claims 5, 28, 51 and 75; p. 822, Table 1
`
`(extracts had from 8.5% to 16.1% free fatty acids)), at least 15% w/w PUFAs
`
`(claims 6, 29, 52, and 76; p. 823, Table 2 (sum of 24.02% PUFAs from table,
`209
`
`
`
`00000209
`
`

`
`Inter Partes Review of US 8,278,351
`Ex. 1042, Brenna Declaration
`
`
`
`1977 sample)), and at least 15% omega-3 fatty acids (claims 9, 32, 55, and 79; p.
`
`823, Table 2 (sum of 21.42% from table, 1977 sample)). Itano teaches
`
`concentrated krill phospholipid extracts having greater than 40% w/w and 45%
`
`w/w phospholipids (p. 16; claims 7, 8, 30, 31, 53, 54, 77, and 78) and greater than
`
`32% and 35% w/w EPA and DHA (p. 16; claims 10, 11, 33, 34, 56, 57, 80 and 81).
`
`The extracts inherently contained the claimed Zn and Se amounts as krill are well
`
`known to contain these elements (WHO Bulletin p. 551, col. 2; claims 12-14, 35-
`
`37, 58-60 and 82-84). With respect to the tables of components listed in claims 15-
`
`18, 38-41, 61-64 and 85-88, Fricke specifically discloses the fatty acid content of
`
`the phospholipid classes (See p. 24, Table 4; claims 15, 38, 61 and 85) and total
`
`lipids (See p. 823, Table 2; claims 16, 39, 62, and 86). Fricke likewise discloses
`
`mono-, di- and triglyceride content and the content of phosphatidylcholine,
`
`phosphatidylethanolamine, sphingomyelin, and cholesterol as well as other
`
`components including saturated, omega-3 and polyunsaturated fatty acid content.
`
`See p. 822, Table 1; p. 823, Table 2; p. 826, Table 7; claims 17, 18, 40, 41, 63, 64,
`
`87 and 88). The extracts inherently contained the claimed individual phospholipid
`
`species listed in claims 19-21, 42-44, 65-67 and 89-91 (See p. 826, Table 6,
`
`discussed above) as well as carotenoids (astaxanthin; claims 22, 23, 45, 46, 68, 69,
`
`92 and 93). Thus, the combined references meet each element of the claims,
`
`
`
`210
`
`00000210
`
`

`
`Inter Partes Review of US 8,278,351
`Ex. 1042, Brenna Declaration
`
`
`
`especially when none of the claimed concentrations of phospholipids and other
`
`lipid extract components are critical as discussed above.
`
`399. Fricke teaches extraction of E. superba with chloroform/methanol.
`
`Bergelson teaches removal of solvents such as chloroform/methanol by rotary
`
`evaporation under mild conditions. Yasawa and Itano teach the desirability of krill
`
`phospholipid compositions
`
`for human consumption, concentrated krill
`
`phospholipid compositions and topical and oral krill oil formulations. The WHO
`
`Bulletin teach the usefulness of krill for a variety of purposes including as a source
`
`of EPA, DHA, Zn, and Se. A person of skill in the art would have been motivated
`
`to combine these references because they teach methods for extraction and
`
`concentration of krill phospholipids and their incorporation into oral and topical
`
`dosage forms as well as into functional foods. There is a reasonable expectation of
`
`success because specific krill phospholipid extracts are disclosed that closely
`
`approximate the claimed values of the ‘351 krill extracts. Formulating the krill
`
`extracts so that they are suitable for human consumption and incorporating the
`
`extracts into oral and topical delivery forms and foods is well within the skill in the
`
`211
`
`art.
`
`
`
`
`
`00000211
`
`

`
`Inter Partes Review of US 8,278,351
`Ex. 1042, Brenna Declaration
`
`400. I further declare that all statement made herein of my own knowledge
`
`
`
`are true and that all statements made on information and belief are believed to be
`
`true; and further that these statements were made with the knowledge that willful
`
`false statements and the like so made are punishable by fine or imprisonment, or
`
`both, under section 1001 of title 18 of the United States Code, and that such willful
`
`false statements may jeopardize the validity of the application or any patent issued
`
`thereon.
`
`Respectfully submitted,
`
`
`
`
`
`
`
`212
`
`00000212
`
`

`
`J. Thomas Brenna, PhD
`
`Curriculum Vitae
`
`Educational and Professional
`
`2000-present Professor of Human Nutrition and of Chemistry and Chemical
`
`September 2013
`
`Biology. Division of Nutritional Sciences, Cornell University, Ithaca,
`
`New York, USA. 1989-1995 Assistant Professor; 1995-2000 Associ-
`
`ate Professor. Member of Cornell Graduate Faculties of Food Science
`
`and Technology, and of Geological Sciences. Since 2012, Professor
`
`of Food Science and Technology.
`
`2006-present Adjunct Professor, Dept of Public Health Sciences, University of
`
`Rochester College of Medicine and Dentistry, Rochester, New York.
`
`2001-2007 Director of Undergraduate Studies, Div of Nutritional Sci, Cornell Uni-
`
`versity, Ithaca, New York.
`
`1985-1989 Staff Scientist, Advanced Technology Development Laboratory, IBM
`
`Corporation, Endicott, NY. Founding Director of the Fourier Transform
`
`Mass Spectrometry Laboratory.
`
`1988-1989 Adjunct Assistant Professor, Dept of Chemistry, Binghamton Universi-
`
`ty, New York.
`
`1985/1982 PhD/MS Chemistry, Cornell University, Ithaca, NY. Thesis advisor: G.
`
`00000213
`
`

`
`Brenna
`H. Morrison.
`
`
`
`
`
`Page 2
`
`1980
`
`BS cum laude, Nutritional Biochemistry, University of Connecticut,
`
`Storrs. Undergrad Research Technician, Lipids Lab (with R. G. Jen-
`
`sen), Dept. of Nutr. Sci., UConn (1978-80).
`
`Professional Experience
`
`Summary: Principal Investigator, National Institutes of Health (NIH) since 1990
`
`(selected): National Institute for General Medical Sciences (R01
`
`GM103437/RR031264, 2010-15; other R01s, 2004-2009, 1992-2006); National
`
`Center for Complementary and Alternative Medicine/Office of Dietary Supple-
`
`ments (R01 AT007003, 2013-2018) NI of Child Health & Human Development
`
`(R21 & R03 2006-2010); National Eye Institute (R01, 1994-2003); United States
`
`Antidoping Agency; Partnership for Clean Competition; numerous industry/private
`
`grants. Our research laboratory averages 10-15 fulltime members and is focused
`
`on fatty acid metabolism, development of high precision isotopic, molecular, and
`
`elemental mass spectrometry for biomedical applications, and high precision iso-
`
`tope ratio mass spectrometry in doping control research.
`
`Author/co-author of >200 peer-reviewed publications; 1 U.S. patent/several pend-
`
`ing. >100 invited presentations
`
`2013 Robert H. Herman Award, American Society for Nutrition. “Given each year
`
`to a clinical investigator whose research work has contributed importantly to the
`
`00000214
`
`

`
`Brenna
`
`
`Page 3
`advancement of clinical nutrition, particularly the biochemical and metabolic
`
`aspects of human nutrition.”
`
`Scientific Service (recent, selected)
`
`• Member, 2015 Dietary Guidelines Advisory Committee. Appointed by US Sec-
`
`retaries of Health and Human Services and of Agriculture.
`
`• President, ISSFAL: International Society for the Study of Fatty Acids and Li-
`
`pids. 2012-2015 President-Elect; 2015-2018 President; 2019-2021 Past-
`
`President. Member, Board of Directors, 2001-2009
`
`• FAO/WHO Expert Consultation on Fats and Fatty Acids in Human Nutrition,
`
`Panelist & author, Geneva, Switzerland, 2008-11.
`
`• Research Proposal Reviews (selected):
`
` NIH: 2013, 2012 Metabolomics Core Facilities; 2010 Shared Research In-
`
`strumentation-Mass Spectrometry (Study Section Chairman); 2008 NIGMS
`
`Large Scale Collaboration (Glue grant) & P01; 2001-2007 Biol Chem & Mac-
`
`romolecular Biophysics Study Section. 2004 Metabolomics Panel, NIH Di-
`
`rector’s Roadmap; 2004 NCI Innovative Technologies for Molecular Analysis
`
`of Cancer; 1997, 2009 NIH Intramural Reviews
`
` World Antidoping Agency (WADA) Research grants program, 2012, 2007.
`
` NSF Major Research Instrumentation, Chemistry Division. 2006, 2004.
`
`00000215
`
`

`
`Brenna
`
`
`Page 4
` Louisiana Board of Regents Chemical Instrumentation Review Panel, 2008,
`
`2005, 2002.
`
`• Expert Witness (selected). Infant nutrition, Federal Court, Eastern District of
`
`Virginia (2009). Gas Chromatography (GC) and GC-combustion isotope ratio
`
`mass spectrometry (GCC-IRMS), American Arbitration Association (2007) and
`
`The Court of Arbitration for Sport (2008).
`
`• Meeting Co-organizer (selected). 2012. 28th ASMS Asilomar Conference:
`
`Mass Spectrometry in Food Safety and Quality. 2011. DHA in Translational
`
`Medicine. Fatty acids and cell signaling (FACS-10), New Orleans, LA (Guest
`
`Editor, Prostaglandins, Leukotrienes, and Essential Fatty Acids (PLEFA)).
`
`2010. A Celebration of DHA, London, UK. 2008. DHA as an Essential Nutri-
`
`ent, Co-editor of PLEFA Supplement. 2007. Fatty acids and cell signaling
`
`(FACS-8), Quebec City, Canada (Guest Editor, PLEFA 77(6): FACS-8 Pro-
`
`ceedings.) 2002, 6th Congress of ISSFAL, Montreal, Canada. Symposia: Li-
`
`pids and mass spectrometry. ASMS 1999 (Portland), 2008 (Denver); 2006
`
`(Cairns) ISSFAL; 2008 (Salt Lake) ABRF.
`
`• Scientific Advisory Boards. 2012-present, First Editor, British Journal of Nutri-
`
`tion; 2006-present, Fats of Life Newsletter
`
`<http://www.fatsoflife.com/index.php>; 2002-present, Editorial Advisory Board,
`
`Rapid Communications in Mass Spectrometry; 2011-present, Metabolism Unit -
`
`Mass Spectrometry Core Lab, Shriners Hospital for Children, Galveston. NY;
`
`00000216
`
`

`
`Brenna
`
`
`Page 5
`1999-present, NIH Center for Biomedical Accelerator Mass Spectrometry, Law-
`
`rence Livermore National Laboratory, Livermore, CA.
`
`• 2000-2004 Member, Publications Committee, American Society for Mass
`
`Spectrometry
`
`Selected Research Funding Awards as Principal Investigator (Total support as PI,
`
`1990-2010, >$15M total; active.)
`
`2013-18 Molecular Mechanism of Omega-3 Response, NIH-NCCAM/ODS (R01)
`
`2010-15 GCx(py)GCC-IRMS for Isotope Metabolomics, NIH-NIGMS (R01)
`
`
`
`2010-13 Branched Chain FA and Gut Development, NIH-Nat Inst Child Health &
`
`Hum Development (R21).
`
`2009-12 Characterization of the Human Urinary Steroidome, Partnership for
`
`Clean Competition.
`
`2006-10 LCPUFA Status and Birth Outcome in India, NIH-Nat Inst Child Health &
`
`Hum Development (R03).
`
`2004-09 Gas phase derivatization for lipidomic MS analysis, NIH-NIGMS (R01)
`
`2006-09 Standardization and Methodology for Steroid Isotopic Analysis, United
`
`States Anti-Doping Agency.
`
`2002-08 LCPUFA supplementation & CNS function, Mead Johnson & Co/Bristol-
`
`Myers Squibb, Evansville, IN.
`
`2005-06 Safety and efficacy of single cell oils, Martek Biosciences, Columbia,
`
`00000217
`
`

`
`Brenna
`MD.
`
`
`
`
`
`Page 6
`
`1992-06 Precise isotope ratio chromatography and stable tracers, NIH-NIGMS
`
`(R01) (incl 2 competitive renewals).
`
`1994-03 Dietary essential fatty acid accumulation in retina, NIH-National Eye
`
`Institute (R01) (incl 1 competitive renewal).
`
`2002-03 Conjugated linoleic acid metabolism in humans, National Cattlemans
`
`Beef Association.
`
`1999-00 Matrix-assisted laser desorption/ionization mass spectrometer, Na-
`
`tional Science Foundation.
`
`1995-99 Natural abundance isotope center, NSF & Mellon Foundation.
`
`1993-94
`
`13C-tracers for environmental analysis, Oak Ridge National Laboratory.
`
`Tennessee.
`
`1991-93 Novel determination of water isotopes, American Chemical Society-
`
`Petroleum Research Fund.
`
`1990-92 Novel water isotope detection by mass spectrometry, NIH-National In-
`
`stitute of Child Health & Human Dev (R03).
`
`Professional Society Memberships:
`
`ASMS: American Society for Mass Spectrometry; ASN: American Society for Nu-
`
`trition; ISSFAL: International Society for the Study of Fatty Acids and Lipids.
`
`ASBMB: American Society for Biochemistry and Molecular Biology. American
`
`Chemical Society 25 year member.
`
`00000218
`
`

`
`Brenna
`
`University/College/Department Service (selected) and Teaching
`
`
`
`Page 7
`
`• Teaching.
`
` Undergraduate. 2012, ongoing: NS 4444, Sports Nutrition and Supple-
`
`ments: Concept and Evidence. 2000-2010: Research in Health and Nutri-
`
`tion; 2000-2010: Undergraduate Honors program director; 1991-2001: NS
`
`332 Methods in Nutritional Science
`
` Graduate. 1992-present: NS 6900/Chem 6280 Isotopic and Trace Element
`
`Analysis. 1988: Binghamton University Graduate Course: Advanced Instru-
`
`mental Surface Characterization.
`
`• Service
`
` Cornell University Athletics: 2007-2010; 1997-2000; 1992-1995 Faculty
`
`Advisory Committee on Athletics and Physical Education (Chair 1993/1994;
`
`1994/1995; 1997/1998). 1998/1999 NCAA Cornell Rev Steering Committee;
`
`1994/1995 Cornell Athletic Director Search. 1998-2013 Cornell Varsity
`
`Softball, Faculty Advisor
`
` University Mass Spectrometry facilities
`
` 1999, Co-Founder, Cornell Biotechnology proteomics/small molecule
`
`mass spectrometry facility, funded by an NIH shared instrumentation
`
`grant (PI). Currently designated faculty facility advisor.
`
` 1995, Co-Founder, Cornell Isotope Laboratory (COIL), an isotope ratio
`
`00000219
`
`

`
`Brenna
`
`
`
`Page 8
`mass spectrometry service facility funded by NSF and the Mellon Foun-
`
`dation (one of 5 PIs).
`
` University (other): 2013-2015, 2001-2004, 1994-1995 Cornell Faculty
`
`Senate; 1994-1995 Dean’s Committee on Faculty Governance.
`
` College: 2001-2007 College of Human Ecology Educational Policy Com-
`
`mittee; 2006/07 Chair; 1995/1996, Chair 1996/1997 & 1997/1998 Col of
`
`Human Ecology Committee on Academic Status
`
`00000220
`
`

`
`Brenna
`
`Publications
`
`
`
`
`
`Page 9
`
`I. Peer Reviewed Journal Articles/Book Chapters/Gene Sequence post-
`
`ings/Letters and comments
`
`II. Selected Invited Lectures
`
`III. General/Popular Press Articles
`
`IV. Conference Presentations/Abstracts/Extended Abstracts
`
`I. Peer Reviewed Journal Articles/Book Chapters/ Gene Sequence postings
`
`(>200 total)
`
`Comment on Rizos et al., JAMA 2012, September 12 ; 308(10):1024-1033. Clau-
`
`dio Galli and J. Thomas Brenna. Journal of the American Medical Association
`
`309(1): 27, 2013.
`
`Fatty Acid Analysis By High Resolution Gas Chromatography and Mass Spec-
`
`trometry for Clinical and Experimental Applications. J. Thomas Brenna. Current
`
`Opinion
`
`in Clinical Nutrition and Metabolic Care, 2013;16(5):548-54. doi:
`
`10.1097/MCO.0b013e328363bc0a. PMID: 23892505.
`
`Branched Chain Fatty Acids (BCFA) in the neonatal gut, and estimated dietary in-
`
`take in infancy and adulthood. Rinat R. Ran-Ressler, Raymond P Glahn,
`
`SangEun Bae, J. Thomas Brenna, Nestlé Nutrition Institute Workshops Series 77,
`
`2013, in press.
`
`00000221
`
`

`
`Brenna
`
`
`Page 10
`Disturbance in uniformly 13C-labelled docosahexaenoic acid metabolism in elderly
`
`humans carrying apolipoprotein E4 allele. Chouinard-Watkins R, Rioux-Perreault
`
`C, Fortier M, Tremblay-Mercier J, Zhang Y, Lawrence P,Vohl MC, Perron P, Lor-
`
`rain D, Brenna JT, Cunnane SC, Plourde M. British Journal of Nutrition 2013, in
`
`press.
`
`Plasma Oxylipin Profiling Identifies Polyunsaturated Vicinal Diols As Responsive
`
`To Arachidonic Acid (ARA) And Docosahexaenoic Acid (DHA) Intake In Growing
`
`Piglets. MJ Bruins, AD Dane, K Strassburg, RJ Vreeken, JW Newman, N Salem
`
`Jr, C Tyburczy, JT Brenna, Journal of Lipid Research 2013, Jun;54(6):1598-607.
`
`PMID: 23543770; PubMed Central PMCID: PMC3646461.
`
`Docosahexaenoic Acid and Human Brain Development: Evidence A Dietary Sup-
`
`ply is Needed for Optimal Development. J. Thomas Brenna, Susan E. Carlson.
`
`The Journal of Human Evolution, in press, 2013.
`
`Interruption of scheduled, automatic feeding and reduction of excess energy in-
`
`take in toddlers. Ciampolini M, Brenna JT, Giannellini V, Bini S. International
`
`Journal of General Medicine. 2013;6:39-47. PMID: 23393411 [PubMed] PMCID:
`
`PMC3565931 doi: 10.2147/IJGM.S39946. Epub 2013 Jan 31.
`
`Effects of Low-Dose Aspirin and Fish Oil on Platelet Function and NFkappaB in
`
`Adults with Diabetes Mellitus, Robert C Block, Amir Abdolahi, Brian Smith, N
`
`Meednu, Kelly Thevenet-Morrison, Xueya Cai, Huadong Cui, Shaker Mousa, J.
`
`00000222
`
`

`
`Brenna
`
`
`Page 11
`Thomas Brenna, S Georas, Prostaglandins, Leukotrienes, and Essential Fatty Ac-
`
`ids, 2013, 89(1):9-18. PMCID: PMC3589139. PMID: 23664596.
`
`Commentary on ‘Maternal long-chain PUFA supplementation during protein defi-
`
`ciency improves brain fatty acid accretion in rat pups by altering the milk fatty acid
`
`composition of the dam’, J. T. Brenna. Journal of Nutritional Sciences 2:e4, 2013.
`
`Steric Effects in the interaction between Transmembrane Proteins and Polyun-
`
`saturated Phospholipids. Khatuna Kachlishvili and J. Thomas Brenna, Journal of
`
`Biological Physics and Chemistry, 2013; 13: 36-44.
`
`Pregnancy alters choline metabolism in women consuming methyl-d9-choline.
`
`Jian Yan, Xinyin Jiang, Allyson A. West, Cydne A. Perry, Olga V. Malysheva, J
`
`Thomas Brenna, Sally P. Stabler, Robert H. Allen, Marie A. Caudill. Submitted,
`
`2013.
`
`Isotope Protection of Polyunsaturated Fatty Acids against Lipid Peroxidation: a
`
`Novel Approach to Mitigating Mitochondrial Neurological Diseases. Mikhail S.
`
`Shchepinov, Vitaly A. Roginsky, J. Thomas Brenna, Robert J. Molinari, Randy To,
`
`Hui Tsui, Catherine F. Clarke and Amy B. Manning-Boǧ. Submitted, 2013.
`
`Dietary arachidonic acid and docosahexaenoic acid regulate liver fatty acid de-
`
`saturase (FADS) alternative transcript expression in suckling piglets. Vasuki Wi-
`
`jendran, Ian Downs, Cynthia Tyburczy, Kumar S. D. Kothapalli, Woo Jung Park,
`
`00000223
`
`

`
`Brenna
`
`
`Page 12
`Bryant S. Blank, J. Paul Zimmer, C.M. Butt, Norman Salem, Jr., J. Thomas Bren-
`
`na, Prostaglandins, Leukotrienes, and Essential Fatty Acids, 2013, in press.
`
`Metabolism of 13C-docosahexaenoic acid before and after fish oil supplementa-
`
`tion in healthy older individuals. Plourde M, Chouinard-Watkins R, Rioux-
`
`Perreault C, Fortier M, Dang TM, Allard MJ, Tremblay-Mercier J, Zhang Y, Law-
`
`rence P, Vohl MC, Perron P, Lorrain D, Brenna JT, Cunnane SC, 2013, submitted.
`
`A novel FADS1 isoform potentiates FADS2-mediated production of eicosanoid
`
`precursor fatty acids.. Woo Jung Park, Kumar S.D. Kothapalli, Holly T. Reardon,
`
`Peter Lawrence, Shu-Bing Qian, J. Thomas Brenna, Journal of Lipid Research
`
`53(8):1502-12, 2012. PMID: 22619218.
`
`Insertion-deletions in a FADS2 intron 1 conserved regulatory locus control expres-
`
`sion of fatty acid desaturases 1 and 2 and modulate response to simvastatin. Hol-
`
`ly T. Reardon, Jimmy Zhang, Kumar S.D. Kothapalli, Andrea J. Kim, Woo Jung
`
`Park, and J. Thomas Brenna, PLEFA 2012, 87(1) 25-33. PMID: 22748975.
`
`Structural Characterization of Saturated Branched Chain Fatty Acid Methyl Esters
`
`by Collisional Dissociation of Electron Impact Activated Molecular Ions. Rinat
`
`Ran-Ressler, Peter Lawrence, J. Thomas Brenna, Journal of Lipid Research
`
`53(1):195-203, 2012. PMID: 22021637.
`
`Production of isotopically-labeled standards from a uniformly labele

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket